Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The breakthrough therapy designation has been given to olverembatinib as a treatment for succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) patients who have received first-line treatment. The designation was based […]
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). The goal of the study being held in China is to assess the efficacy and safety of parsaclisib in patients having recurrent or refractory follicular lymphoma or marginal zone lymphoma […]
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]
